Introduction
============

The composition of the microbial respiratory flora of cystic fibrosis (CF) patients changes with age; *Haemophilus influenzae* and *Staphylococcus aureus* being present mainly in young children, while *Pseudomonas aeruginosa, S. aureus,* and *Burkholderia* sp. predominate in older patients ([@B19]; [@B8]; [@B26]). At the age of 20, 60--70% of CF-patients present intermittent colonization by *P. aeruginosa* ([@B17]) which progressively evolves toward a chronic colonization, that entails progressive lung tissue damage and impairment of pulmonary function. The disappearance of the early colonizing species may be explained by antibiotic treatments or by competition between co-colonizing microorganisms. Many ecological factors, including host immune responses as well as the presence of co-colonizing species interacting with*P. aeruginosa* by competition and/or cooperation, determine the dynamics of lung colonization. Bacterial interference occurs either via direct competition characterized by an active mechanism including the type VI secretion systems ([@B33]; [@B1]) and production of competitor molecules (siderophores, secondary metabolites, toxins), or via exploitative competition where one organism consumes the resources of another ([@B7]; [@B2]). For example, *P. aeruginosa* can lyse*S. aureus* to obtain iron under iron-starvation conditions using LasA protease ([@B29]), and 4-hydroxy-2-heptylquinoline *N*-oxide (HQNO) allows *P. aeruginosa* to inhibit the cytochrome oxidase of *S. aureus* ([@B25]; [@B27]; [@B39]). Furthermore, recent results demonstrated that compounds such as phenazines inhibit methicillin-resistant *S. aureus* (MRSA; [@B5]). Besides active competition, regulatory effects induced for instance by the resident flora can induce the expression of important virulence and metabolic genes in *P. aeruginosa* ([@B11]). In addition, positive interactions can also occur between microorganisms during polymicrobial infections. For example, *P. aeruginosa* can induce the formation of small colony variants in *S. aureus,* leading to an increased resistance of the latter to aminoglycoside antibiotics ([@B20]). This indicates that interspecies competition and cooperation play an important role in shaping composition and structure of polymicrobial bacterial populations, thereby potentially influencing disease progression. Increasing our understanding of these interactions is crucial ([@B3]) and might lead to the identification of new targets aiming at manipulating interactions inside polymicrobial communities to the disadvantage of pathogens such as *P. aeruginosa*.

In this perspective we developed a broad genetic screen to identify*P. aeruginosa* genes required for direct and exploitative competition. We searched for *P. aeruginosa* mutants affected in growth in the presence of *S. aureus*, *Klebsiella pneumoniae,* or *B. cepacia*. In addition, we examined *P. aeruginosa* mutants altered in their capacity to inhibit growth of *S. aureus*.

Materials and Methods {#s1}
=====================

Bacterial Strains, Growth Conditions and Media
----------------------------------------------

All *P. aeruginosa* mutants used in this study are derived from the clinical strain PA14 ([@B34]; **Table [1](#T1){ref-type="table"}**). All genetic manipulations were performed in *Escherichia coli* strain DH10B. *E. coli* strain SM10-check λpir was used for conjugating plasmids into *P. aeruginosa.* Three bacterial pathogens were used for the initial screening: the *S. aureus* clinical strain COL ([@B13]), a clinical *Burkholderia cenocepacia* isolate (University Hospitals of Geneva) and a non-capsulated *K. pneumoniae* strain (laboratory collection). The *S. epidermidis* and the *E. coli* strains were isolated from tracheal aspirates of two CF patients followed at the University Hospitals of Geneva (Geneva, Switzerland).

###### 

Plasmids and strains.

  Plasmids or strains                    Description                                                                                                                                                       Reference
  -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  **Plasmids**                                                                                                                                                                                             
  pIApX2                                 Broad-host-range cloning vector, pUCP20 derivative                                                                                                                I. Attree (Grenoble, France; [@B44])
  pME3087                                Mobilizable suicide vector, ColE1                                                                                                                                 [@B43]
  pMMB207                                Expression plasmid with inducible tac/lacUV5 promoter                                                                                                             [@B30]
  pPqsCDE                                *pqsCDE* PCR fragment cloned into pIApX2 by using XbaI (Roche) and HindIII (Roche)                                                                                This study
  pCarB                                  *carB* PCR fragment cloned into pIApX2 by using HindIII (Roche) and BamHI (Roche)                                                                                 This study
  pBioA                                  *bioA* PCR fragment cloned into pMMB207 by using KpnI (NEB) and BamHI (Roche)                                                                                     This study
  pPurF                                  *purF* PCR fragment cloned into pMMB207 by using KpnI (NEB) and BamHI (Roche)                                                                                     This study
  **Strains**                                                                                                                                                                                              
  PA14                                   Clinical isolate UCBPP-PA14                                                                                                                                       [@B34]
  PA14 *carB*::Tn                        Transposon inserted into the *carB* gene                                                                                                                          This study
  PA14 *pqsC*::Tn                        Transposon inserted into the *pqsC* gene                                                                                                                          This study
  PA14 *purF*::Tn                        Transposon inserted into the *purF* gene                                                                                                                          This study
  PA14 *bioA::*Tn                        Transposon inserted into the *bioA* gene                                                                                                                          This study
  PA14 *carB*::Tn pCarB                  *carB*-disrupted*Pseudomonas aeruginosa* containing the pCarB complementation plasmid                                                                             This study
  PA14 *pqsC*::Tn pPqsCDE                *pqsC*-disrupted*P. aeruginosa* containing the pPqsCDE complementation plasmid                                                                                    This study
  PA14 *purF*::Tn pPurF                  *purF-*disrupted*P. aeruginosa* containing the pPurF complementation plasmid                                                                                      This study
  PA14 *bioA*::Tn pBioA                  *bioA-*disrupted*P. aeruginosa* containing the pBioA complementation plasmid                                                                                      This study
  PA14 *carB*::Tn pIApX2                 *carB*-disrupted*P. aeruginosa* containing the pIApX2 plasmid                                                                                                     This study
  PA14 *pqsC*::Tn pIApX2                 *pqsC*-disrupted*P. aeruginosa* containing the pIApX2 plasmid                                                                                                     This study
  PA14 *purF::*Tn pMMB207                *purF-*disrupted*P. aeruginosa* containing the pMMB207 plasmid                                                                                                    This study
  PA14 *bioA::*Tn pMMB207                *bioA-*disrupted*P. aeruginosa* containing the pMMB207 plasmid                                                                                                    This study
  PA14 Δ *lasA*                          *LasA*-deleted*P. aeruginosa* PA14 strain                                                                                                                         This study
  PAO1 Δ *pqsA pqsA*::*lux*              *PqsA*-deleted *P. aeruginosa* PAO1 strain with a copy of the *pqsA* promoter linked to the *luxCDABE* genes and inserted into a neutral site in the chromosome   [@B16]
  PA14*mvfR^-^*                          Mutated PA14 strain containing a nonsense point mutation in *mvfR*                                                                                                [@B4]
  PA14*pqsA^-^*                          Mutated PA14 strain containing a non-polar deletion of *pqsA*                                                                                                     [@B10]
  PA14 *pqsH*^-^                         Mutated PA14 strain containing a *aacC1* cassette inserted into *pqsH*                                                                                            [@B47]
  PA14 *pqsL*^-^                         Isogenic non-polar*pqsL* deletion mutant                                                                                                                          [@B24]
  *Escherichia coli* SM10-check λ*pir*   RP4-2-Tc::Mu *recA, pir* lysogen KmR                                                                                                                              [@B37]
  *Staphylococcus aureus* COL            Clinical strain, MRSA                                                                                                                                             [@B13]
  *Burkholderia cenocepacia*             Clinical strain                                                                                                                                                   University Hospitals of Geneva
  *Klebsiella pneumoniae*                Non-capsulated                                                                                                                                                    Laboratory collection
  *E. coli*                              Clinical strain from CF-patient                                                                                                                                   This study
  *S. epidermidis*                       Clinical strain from CF-patient                                                                                                                                   This study

When required, plates were supplemented with 1 mM uracil, 1 mM arginine, or 2 mg/L biotin (final concentrations). For growth under hypoxic conditions, LB plates were supplemented with 5 mM KNO~3~ and incubated in a jar using the GasPak Plus kit (BBL) (final O~2~ concentration \< 0.2%).

Generation of the *P. aeruginosa* PA14 Transposon (Tn) Mutant Library
---------------------------------------------------------------------

The *E. coli* SM10-check λ*pir* donor strain containing pBT20 ([@B23]) and the recipient *P. aeruginosa* PA14 were grown overnight at 37°C with shaking (250 rpm) in LB-broth. 200 μL of the donor and 100 μL of the recipient culture were mixed and centrifuged at 6,000 rpm for 2 min. The pellet was resuspended in 20 μL of LB and deposited on an LB agar plate. After 5 h of incubation at 37°C, cells were resuspended in 1 mL 0.9% NaCl and 100 μL of the suspension were plated on LB agar medium containing gentamicin (50 mg/L) and chloramphenicol (10 mg/L). To test for random distribution of Tn-insertions, 200 transconjugants were picked and streaked on minimal M9-salts medium supplemented with 0.2% glucose and 1 mM MgSO~4~ and on an LB-agar plate. Approximately 1% of clones were auxotrophic, which is agreement with a random transposition event.

Growth Competition Screening
----------------------------

Overnight cultures of bacterial competitors were adjusted to OD~600~ = 0.5. A 500 μL aliquot of fivefold (*S. aureus* and *S. epidermidis*) and 100-fold (*B. cepacia*, *K. pneumoniae,* and *E. coli*) dilutions were plated on agar plates. Bacterial lawns were incubated 2 h at 37°C. Overnight cultures of *P. aeruginosa* transposon mutants were adjusted to OD~600~ = 2 and 1 μL of each culture was spotted on the competitor lawns using a 48-pin inoculator. As control, cells were spotted on a plate without competitors. Plates were incubated 18 h at 37°C. Mutants were initially screened for: (i) an alteration of the inhibition zone on the *S. aureus* lawn on Mueller Hinton agar, and (ii) an alteration of *P. aeruginosa* growth on lawns of *B. cepacia* and *K. pneumoniae* on LB-agar.

Identification of the Transposon Insertion Site
-----------------------------------------------

The transposon insertion site was identified by a two-step semi-random PCR ([@B18]; [@B23]). The first round PCR reaction contained dNTPs (0.25 mM final), Taq Buffer (1X final, Sigma), DMSO (5% final concentration), Taq polymerase (2.5 U/reaction, Sigma), and primers MCL195 and ARB1 (**Table [2](#T2){ref-type="table"}**). Four microliters of bacterial lysate served as template. PCR cycling conditions were as follows: 95°C for 3 min, 36 cycles of 95°C for 20 s, 30 to 48°C for 40 s with a 0.5°C increase per cycle, 72°C for 1 min and a final extension at 72°C for 5 min. In the second round PCR reaction the nested primers ARB2 and MCL210 were used (**Table [2](#T2){ref-type="table"}**). PCR conditions were as follows: 95°C for 3 min, 30 cycles of 95°C for 30 s, 50°C for 30 s, 72°C for 1 min and a final extension of 72°C for 4 min. PCR products were visualized on a 1.6% agarose gel. The most intense bands were extracted and purified (GeneJet Gel extraction kit, ThermoScientific). The PCR products were then submitted to DNA sequencing (Fasteris SA, Geneva, Switzerland) using the nested primers ARB2 and MCL210. Each sequence was aligned to the PA14 genome sequence in the *Pseudomonas* database ([@B45]). Confirmation of the transposon insertion was done by PCR using gene and/or transposon specific primers. PCR cycling conditions were: (i) activation: 95°C for 2 min, (ii) denaturation: 95°C for 20 s, annealing: 57°C for 30 s, extension: 72°C for 1 min and 30 s, (iii) final extension: 72°C for 4 min. Step 2 was repeated 27 times. PCR products were purified and submitted to DNA sequencing.

###### 

Primers used in this study

  Primers                                                                     Amplified gene(s)    Sequences (5^′^--3^′^)                   Final concentration (μM)
  --------------------------------------------------------------------------- -------------------- ---------------------------------------- --------------------------
  **Semirandom PCR**                                                                                                                        
  ARB1                                                                                             GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT      0.5
  ARB2                                                                                             GGCCACGCGTCGACTAGTAC                     0.4
  MCL195                                                                                           GATCCCGCAGTGGCTCTCTATACAAAGTTG           0.2
  MCL210                                                                                           TGGTGCTGACCCCGGATGAAG                    0.4
  **Confirmation of the transposon insertion site and complementations^∗^**                                                                 
  PurF-Kpn                                                                    *purF*               ACA[GGTACC]{.ul}AGTGATTTTGGCGGGACAC      0.6
  PurF-BamHI                                                                                       ACA[GGATCC]{.ul}CCAGGGTGTCGAAGGCC        0.6
  BioA-Kpn                                                                    *bioA*               ACAGGTACCTGAACACCCCCAACATGAGA            0.6
  BioA-R_BamHI                                                                                     ACA[GGATCC]{.ul}GATTCGAGGGTAGTGGCGAC     0.6
  CarB-F_BamHI                                                                *carB*               ACA[GGATCC]{.ul}GTTCGTCGATCCCGGCTA       0.6
  CarB-R_HindIII                                                                                   ACA[AAGCTT]{.ul}TCGGCGTTTTCCTTGAGG       0.6
  pqsC-Xba                                                                    *pqsCDE*             ACAC[TCTAGA]{.ul}TTCGAACTGGCGTCGCAAC     0.6
  pqsC-Hind                                                                                        ACAC[AAGCTT]{.ul}TCTTCCAGTCGATAGCCAACC   0.6
  ***lasA* deletion^∗^**                                                                                                                    
  LasAF-Eco                                                                   5^′^ *lasA* region   CCCG[GAATTC]{.ul}AGGATAACGTCGGCATGGAC    0.6
  LasAR-Bam                                                                                        CCGC[GGATCC]{.ul}TGCTCCAGGTATTCGCTCTTG   0.6
  LasAF-Bam                                                                   3^′^ *lasA* region   CCGC[GGATCC]{.ul}ACCAGATCCAGGTGAGCAACG   0.6
  LasAR-Hind                                                                                       CCCC[AAGCTT]{.ul}TCGGAGTCCGGCTACTACGC    0.6

∗

Restriction enzyme recognition sites are underlined

Exoproduct Analysis
-------------------

Rhamnolipid production was assessed following a previously described protocol ([@B22]). Plates were incubated 18 h at 37°C, 24 h at room temperature and then 16 h at 4°C. The diameter of the rhamnolipid-containing halo formed around the bacterial colony was measured and compared with that produced by the reference strain PA14. Determinations were done in duplicates.

Elastase activity was determined using the Elastin Congo Red assay with modifications ([@B32]). Overnight cultures of *P. aeruginosa* strains were prepared in LB medium supplemented with 1 mM uracil to optimize the growth of the strain PA14 *carB*::Tn. Cultures were grown for 7 h at 37°C in PB medium ([@B14]). The OD~600~ was measured and elastase activity determined in supernatants using the Elastin Congo Red assay measuring absorption at OD~495~. All determinations were done in triplicate and expressed as the ratio of OD~495~/OD~600~.

Extra-Chromosomal Complementations
----------------------------------

The coding regions of *carB*, *pqsCDE*,*bioA,* and*purF* including 100 nucleotides upstream of the start codon were amplified by PCR from PA14 genomic DNA using the primers listed in **Table [2](#T2){ref-type="table"}** and following the same PCR conditions as described above. PCR products were purified and cloned into vectors pIApX2 (*pqsCDE*, *carB*) or pMMB207 (*purF*, *bioA*; [@B30]; [@B44]; **Table [1](#T1){ref-type="table"}**). 1.5 μg of each vector and insert were digested with the appropriate restriction enzymes and buffers in a final volume of 25 μL (**Table [1](#T1){ref-type="table"}**). After purification on agarose gel (GeneJet Gel extraction kit, ThermoScientific), vectors and inserts were ligated (T4 DNA ligase, Promega). *E. coli* DH10B thermo-competent cells were transformed with the ligation mixture and transformants selected on LB plates supplemented with 100 μg/mL ampicillin (*pqsCDE*, *carB*) or 15 μg/mL chloramphenicol (*purF*, *bioA*). The resulting plasmids pCarB and pPqsCDE were electroporated into the corresponding PA14 Tn-mutants and selected on LB-agar plates supplemented with 200 μg/mL carbenicillin. Plasmids pPurF and pBioA were transferred into the corresponding PA14 Tn-mutants by triparental mating using pRK2013 as a helper plasmid ([@B15]). Transconjugants were selected on LB-agar plates supplemented with 250 μg/mL chloramphenicol and 25 μg/mL gentamycin to counterselect *E. coli* donor strains.

Construction of the *P. aeruginosa lasA* Mutant
-----------------------------------------------

A *lasA* deletion mutant was constructed by homologous recombination using plasmid pME3087 ([@B43]). For the 5^′^-region PCR fragment, we used dNTP (0.2 mM final), Taq Buffer (1X final, Sigma), DMSO (5% final), Taq polymerase (2.5 U/reaction), and 4 μL of PA14 lysate. PCR conditions were as follows: one cycle of 2 min at 95°C, 27 cycles of 20 s at 95°C, 30 s at 57°C, 1 min at 72°C followed by a final extension of 4 min at 72°C. For the 3^′^-region PCR fragment, we used dNTP (0.2 mM final), PFU Buffer (1X final), DMSO (5% final), PFU polymerase (2.5 U/reaction), and 4 μL of PA14 bacterial lysate. PCR conditions were as follows: one cycle of 95°C for 2 min, 30 cycles of 20 s at 95°C, 30 s at 55°C, 1 min at 72°C, followed by a final extension of 4 min at 72°C. The 5^′^-region and the 3^′^ region fragments were digested with BamHI. Both fragments were ligated and PCR re-amplified using primers LasAF-Eco and LasAR-Hind (**Table [2](#T2){ref-type="table"}**). The generated 1.6 kbp fragment was digested using *Eco*RI and *Hin*dIII restriction enzymes and cloned into plasmid pME3087. The resulting plasmid plasA1 was introduced into *E. coli* strain SM10lpir for subsequent conjugation into *P. aeruginosa* PA14. Transductants were selected on M9-agar plates supplemented with 25 μM citrate and 1 mM MgSO~4~ and 75 μg/mL tetracycline (Tc). Individual colonies were repurified on LB-agar plates containing 75 μg/mL Tc. Putative *lasR* deletion mutants generated after the second recombination event were enriched by carbenicillin-treatment as described previously ([@B43]). Surviving cells, which were Tc-susceptible were screened by PCR for loss of a 300 bp fragment in the *lasA* gene. One of three clones was selected for further analysis.

Inhibition and Lytic Activity of *P. aeruginosa* Supernatants on *S. aureus*
----------------------------------------------------------------------------

We measured both inhibition of the *S. aureus* growth as well as lysis of *S. aureus* cells by *P. aeruginosa* supernatants.

The inhibition capacity of *P. aeruginosa* supernatants on *S. aureus* growth was tested in liquid. Overnight cultures of *P. aeruginosa* grown in MH-broth were centrifuged and the resulted supernatants were filtered (0.22 μm, Millipore). An overnight culture of *S. aureus* strain COL was adjusted to an OD~600~ of 0.1 in MH-broth. 100 μL of this bacterial suspension was incubated with 100 μL of *P. aeruginosa* supernatant. All mixtures were incubated in triplicate at 37°C with intermittent shaking and OD~600~ was recorded for 10 h in a plate reader (BioTek Synergy H1).

The lytic activity of *P. aeruginosa* overnight culture supernatants on *S. aureus* was tested on LB medium, supplemented or not with 1 mM uracil. The overnight cultures of *P. aeruginosa* were adjusted to the same OD~600~ before pelleting cells by centrifugation (6,000 × *g*, 10 min). Supernatants were filtered (0.22 μm) and used immediately. An overnight culture of *S. aureus* strain COL was adjusted to OD~600~ = 1 in 0.02 M Tris-HCl pH 7.5 and cells were inactivated by heating at 95°C for 10 min. 100 μL of the *S. aureus* bacterial suspension was incubated with 100 μL of filtered *P. aeruginosa* supernatants. Mixtures were incubated at 37°C with intermittent shaking and OD~600~ was recorded during 8 h in a plate reader (BioTek Synergy H1).

Quantification of PQS Production
--------------------------------

To test whether *S. aureus* affects PQS production by *P. aeruginosa*, an overnight culture of *S. aureus* strain COL was adjusted to an OD~600~ = 0.1 in LB medium. 190 uL of this dilution was deposited in a 96 well plate and incubated for 2 h without shaking. During this incubation, *P. aeruginosa* overnight cultures were centrifuged (6,000 rpm, 3 min) and the pellet adjusted to an OD~600~ = 2 in 0.9% NaCl. 5 μL of this cell suspensions of the *P. aeruginosa* PA14 and PA14 carB mutant were combined with 5 μL of the cell suspension of the PQS-indicator strain PA14 Δ*pqsA pqsA*::*lux* culture ([@B16]) and added to the 190 μL of the pre-incubated *S. aureus* cultures. The microtiter plate was incubated at 37°C with intermittent shaking and optical density at 600 nm and luminescence were recorded after 6 h. Experiments were done in duplicate.

Growth Competition Assay with Supernatants of Competitor Cultures
-----------------------------------------------------------------

*Pseudomonas aeruginosa* cultures were also spotted on MH-plates seeded with 500 μl of filtered supernatants from overnight competitor cultures. Overnight (18 h) cultures of competitor bacteria were centrifuged 10 min at 6,000 rpm. Supernatants were filtered (0.22 μm) and 500 μL of the filtrate was spread on agar plates. *P. aeruginosa* cultures were prepared as described above.

Results
=======

Generation of the *P. aeruginosa* PA14 Transposon Insertion Library and Selection of Mutants Affected in their Capacity to Compete with other Respiratory Pathogens
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

We generated a library of 2,288 transposon insertion mutants in *P. aeruginosa* strain PA14. Three bacterial pathogens also commonly found in the lungs of CF patients were selected for the initial competition screening: *S. aureus*, *B. cepacia*, and *K. pneumoniae*. The PA14 mutant library was screened for: (i) an alteration of the inhibition zone produced by *P. aeruginosa* on a lawn of *S. aureus* (**Figure [1A](#F1){ref-type="fig"}**), and (ii) an alteration of *P. aeruginosa* growth in the presence of *B. cepacia* and *K. pneumoniae* (**Figure [1B](#F1){ref-type="fig"}**). Based on this screening, 64 mutants were retained displaying an altered inhibition zone (35 mutants) or growth (25 mutants) or both (4) in the presence of competitors when compared to wild-type PA14. Each of the selected mutants was re-tested in quadruplicates and four yielded reproducible phenotypes. Two mutants showed a reduction of the inhibition zone on a lawn of*S. aureus,* while the two others were affected in growth on lawns of *K. pneumoniae* or *B. cepacia*. Growth of these mutants was not affected on agar plates in the absence of competitors (data not shown).

![**Selection of *Pseudomonas aeruginosa* mutants affected in competition with bacterial pathogens. (A)** *P. aeruginosa* Tn-mutants were spotted on *Staphylococcus aureus* bacterial lawn on MH-agar plate. This panel shows an example of a mutant displaying an altered inhibition zone compared to the others, indicating that this mutant is not able to compete with *S. aureus*. **(B)***P. aeruginosa* Tn-mutants were spotted on LB agar plate with or without *Klebsiella pneumoniae*. The unbroken line shows a mutant drastically affected by the presence of *K. pneumoniae* whereas it had a normal growth on plate without competitor.](fmicb-06-00321-g001){#F1}

Role of the *P. aeruginosa pqs* Pathway During Competition with *S. aureus*
---------------------------------------------------------------------------

We determined the transposon insertion site in the *P. aeruginosa* clone most affected in inhibition of *S. aureus* growth, by a two-step semi-random PCR. The transposon was inserted at nucleotide position 136 of the *pqsC* gene, which belongs to the *pqsABCDE* operon ([@B48]). A *pqsC* mutant is deficient for the production of 4-hydroxy-2-alkylquinolines (HAQs; [@B12]). We complemented our *pqsC* transposon mutant by introducing a plasmid-encoded copy of the*pqsCDE* genes from PA14. The complemented mutant showed a partial restoration of the wild-type inhibition zone (**Figure [2A](#F2){ref-type="fig"}**). Because*pqsC* is part of a multigene operon, we tested the phenotype of strains mutated in other genes belonging to the PQS biosynthesis pathway. As expected, PA14 derivatives mutated in *pqsA* or*mvfR* (*pqsR*), both deficient in HAQ biosynthesis, did not inhibit *S. aureus* growth (**Figure [2A](#F2){ref-type="fig"}**). The same phenotype was observed for the *pqsH* mutant.

![**Role of the *pqs* pathway of *P. aeruginosa* in direct competition with *S. aureus*. (A)** Effect of *pqsC* disruption on the inhibition of *S. aureus* growth. Spots of *P. aeruginosa* cultures were deposited on LB agar plates seeded with a lawn of *S. aureus* strain COL. Inhibition zone diameters were measured, normalized against the diameter of the corresponding spots and expressed as a percentage against the wild-type PA14 values. Error bars are standard deviations calculated on at least four replicates. Statistical significance was determined by using a *t*-test with unequal variances (^∗^*p* \< 0.01). **(B)** Inhibition activity of *P. aeruginosa* supernatants on *S. aureus* growth. Supernatants of *P. aeruginosa* overnight cultures were incorporated on *S. aureus* cells. *S. aureus* growth (OD~600~) was monitored during 10 h at 37°C in presence to these supernatants. **(C)** Lytic activity of *P. aeruginosa* supernatants on inactivated *S. aureus* cells. Supernatants of *P. aeruginosa* overnight cultures were incorporated on heat-inactivated *S. aureus* cells. OD~600~ was monitored during 8 h at 37°C in presence to these supernatants to evaluate *S. aureus* lysis. **(D)** Role of the *pqs* pathway in hypoxic conditions. Spots of *P. aeruginosa* cultures were deposited on LB agar plates cover by a *S. aureus* lawn. Plates were incubated during 48 h in hypoxic conditions.](fmicb-06-00321-g002){#F2}

To test whether these phenotypes were limited to growth on solid medium, supernatants of *P. aeruginosa* overnight cultures were incubated together with a cell suspension of the *S. aureus* strain COL. Whereas supernatant of wild-type PA14 inhibited growth of *S. aureus*, supernatants from *pqsA*, *pqsC*, *mvfR,* and *pqsH* mutants showed no inhibitory activity. In agreement with the data obtained on solid medium, the *pqsL* mutant showed a partial inhibition of *S. aureus* growth in liquid medium (**Figure [2B](#F2){ref-type="fig"}**).

The LasA staphylolytic protease of *P. aeruginosa* cleaves the pentaglycine cross-links in the peptidoglycan of *S. aureus* leading to cell lysis ([@B21]). We therefore tested the supernatant of a *lasA* mutant in competition with *S. aureus*, which did not alter the wild-type inhibition profile comparable to the one of the wild-type PA14 in our model (**Figure [2B](#F2){ref-type="fig"}**). These results demonstrate that the observed inhibition profile is not the consequence of the expression of LasA, but can be associated to the *pqs* pathway activity in wild-type PA14. To further distinguish between inhibition and lytic activity, we performed the same experiment on heat-inactivated staphylococcal cells (**Figure [2C](#F2){ref-type="fig"}**). Optical density related to *S. aureus* cells rapidly decreased after addition of PA14 supernatants. We observed the same profile with the *pqsC* mutant, indicating that HAQs do not contribute to *S. aureus* cell lysis but to growth inhibition. In contrast, PA14 Δ *lasA* was affected in its capacity to lyse *S. aureus* as expected from previous reports.

Because products of the PQS pathway are known to suppress growth in Gram-positive bacteria by inhibiting the respiratory chain in aerobic condition, we hypothesized that this phenotype may be abolished under hypoxic conditions. As expected, we observed no inhibition zone even for PA14 under hypoxic conditions (**Figure [2D](#F2){ref-type="fig"}**). Because nitrate is a key compound for the growth of *P. aeruginosa* under hypoxic conditions, we performed the experiment without and with addition of KNO~3~ as terminal electron acceptor. However, addition of KNO~3~ had no effect on the phenotype. This suggests that HAQs are unlikely to play a role in *S. aureus* growth inhibition under hypoxic conditions.

Taken together our experiments suggest that the *lasA* gene product is responsible for the lytic activity of *P. aeruginosa*, while HAQs are responsible for growth inhibition of *S. aureus* under aerobic conditions.

Impact of the *carB* Mutation During Direct Competition between *P. aeruginosa* and *S. aureus*
-----------------------------------------------------------------------------------------------

The second mutant affected in its capacity to inhibit growth, and therefore to compete with *S. aureus,* harbored the transposon inserted at position 1,632 of the *carB* gene (PA14_62910), encoding the large subunit of the carbamoyl phosphate synthase ([@B45]). CarB is involved in the pyrimidine pathway leading to uracil synthesis. Indeed, supplementation with uracil restored growth of the *carB* mutant, but not the *S. aureus* growth inhibition (**Figure [3A](#F3){ref-type="fig"}**). Recently, *pyrF*, another gene required for uracil and pyrimidine synthesis was shown to affect the *quorum-sensing* (QS)-circuit in strain PA14 ([@B41]). We therefore tested the QS-dependent virulence factor production in the *carB* mutant. However, we observed no difference in rhamnolipid (**Figure [3B](#F3){ref-type="fig"}**) and elastase production (**Figure [3C](#F3){ref-type="fig"}**) between the *carB* mutant and the wild-type PA14. To determine if the effect observed with the *carB* mutant during competition with *S. aureus* was due to an alteration of the *pqs* pathway we measured the production of PQS by quantifying luminescence produced by the PAO1Δ*pqsA pqsA*::*lux* reporter strain. The quantity of luminescence produced was identical between the *carB* mutant and the wild-type PA14 strain, indicating that *carB* does not affect the PQS production (**Figure [3D](#F3){ref-type="fig"}**) during competition with *S. aureus*. These results suggest that *carB* is required for inhibition of *S. aureus* growth, through a QS-independent mechanism.

![**Role of the *P. aeruginosa carB* gene during competition with *S. aureus*. (A)** Spots of *P. aeruginosa* cultures were deposited on LB agar plates seeded with a lawn of *S. aureus* strain COL. **(B)** Rhamnolipid production by the wild-type PA14 and the *carB*-disrupted PA14 strains. No difference was observed between the two strains within duplicates indicating that the Rhl *quorum-sensing* (QS) is not affected in the mutant. **(C)** Elastase production by the wild-type PA14 and the *carB*-disrupted PA14. Error bars indicate standard deviations calculated from three experimental replicates. **(D)** Quantification of PQS production during competition with *S. aureus*. The *carB* mutant and the wild-type PA14 strains were both incubated with the competitor and with the PAO1 Δ *pqsA pqsA*::*lux* reporter strain. PQS production was evaluated by quantification of the luminescence produced by the reporter strain in response to the amount of PQS in the medium. Luminescence was quantified after 6 h of incubation at 37°C. Error bars are standard deviations calculated on duplicate.](fmicb-06-00321-g003){#F3}

Role of the *carB* Gene During Competition between *P. aeruginosa*, *B. cepacia,* and *K. pneumoniae*
-----------------------------------------------------------------------------------------------------

Two transposon mutants of *P. aeruginosa* were affected in their growth in the presence of *B. cepacia* and*K. pneumoniae* as competitors. One of these mutants was the *carB* mutant described above. This growth defect was complemented by the addition of a plasmid-encoded copy of *carB*, as well as by the addition of uracil (**Figure [4A](#F4){ref-type="fig"}**). Remarkably, growth of the *carB* mutant was not affected when competing with *E. coli* and *S. epidermidis* (data not shown). In contrast the addition of arginine alone, the second final product of this metabolic pathway (**Figure [5](#F5){ref-type="fig"}**), had no impact on the growth of the *carB* mutant (**Figure [4B](#F4){ref-type="fig"}**). To determine whether soluble factors secreted by the competitors could be involved, we plated supernatants of bacterial competitors on LB-agar plates prior to *P. aeruginosa* spotting. Culture supernatants of *B. cepacia* and *K. pneumoniae* did not affect the growth of the *carB* mutant, suggesting that the presence of metabolically active competing bacteria is required to repress growth of this mutant (**Figure [4A](#F4){ref-type="fig"}**). Taken together, these data demonstrate that the *carB* gene, and by analogy the uracil/pyrimidine biosynthesis, is an essential metabolic pathway for the competition of *P. aeruginosa* against *B. cepacia*, *K. pneumoniae,* and *S. aureus*.

![**Role of the *carB*, *purF* and *bioA* mutations during bacterial interactions between *P. aeruginosa* and other respiratory pathogens. (A--D)** Spots of *P. aeruginosa* cultures were deposited on LB agar **(A,B)** or MH agar plates **(C,D)** seeded with a lawn of *S. aureus*, *K. pneumoniae*, *B. cenocepacia*, or *E. coli*. Bacterial lawns were composed by viable cells (VC) from overnight cultures or by supernatants (S) of filtrated overnight cultures.](fmicb-06-00321-g004){#F4}

![**Schematic summary of the growth phenotypes displayed by the *carB*, *purF,* and *bioA* mutants during interactions with other respiratory pathogens.** Metabolic pathways are based on the Kyoto Encyclopedia of Genes and Genomes databases. Open circles represent no growth, whereas filled circles indicate growth of *P. aeruginosa* mutants.](fmicb-06-00321-g005){#F5}

Effect of the *purF* Mutation on the *P. aeruginosa* Growth in Presence of *B. cepacia*, *K. pneumoniae,* and *E. coli*
-----------------------------------------------------------------------------------------------------------------------

The second mutant with a growth defect in the presence of competitors had the transposon inserted at position 264 of the *purF* (PA14_23920) gene, encoding an amidophosphoribosyl transferase. This protein is a key enzyme of purine metabolism, supplying nucleotides for DNA and RNA synthesis ([@B35]). The *purF*::Tn mutant did not grow when cells were spotted on plates containing lawns of *B. cepacia*, *K. pneumoniae,* and *E. coli* (**Figure [4C](#F4){ref-type="fig"}**). This alteration was complemented by the addition of a plasmid-encoded copy of the *purF* gene. In contrast, the *purF* mutant showed normal growth in the presence of *S. epidermidis* and *S. aureus* (data not shown). As observed above for the *carB* mutant, culture supernatants of competing bacteria did not affect growth of the *purF*-disrupted strain (**Figure [4C](#F4){ref-type="fig"}**). This suggests that the *purF* gene is essential for *P. aeruginosa* growth in presence of the *B. cepacia*, *K. pneumoniae,* and *E. coli.*

Role of the Biotin Synthesis Pathway on Beneficial Interactions between *P. aeruginosa* and other Respiratory Pathogens
-----------------------------------------------------------------------------------------------------------------------

To determine if growth of *P. aeruginosa* can be promoted by the presence of other bacterial pathogens, we screened the transposon library for mutants that grew better in the presence of a competitor than in its absence on rich medium. We identified one transposon mutant that grew poorly on MH-agar, but showed wild-type growth in the presence of *K. pneumoniae* and *E. coli* (**Figure [4D](#F4){ref-type="fig"}**). This growth "enhancement" was not seen in the presence of *B. cepacia*, *S. epidermidis,* and *S. aureus* bacterial lawns (data not shown). We identified the transposon insertion in this mutant at position 474 of the *bioA* (PA14_05460) gene, encoding an adenosylmethionine-8-amino-7-oxononanoate aminotransferase, involved in the biotin biosynthesis pathway ([@B38]). Indeed the addition of biotin, as well as extra-chromosomic complementation with the *bioA* gene, restored growth of the *bioA*-disrupted mutant (**Figure [4D](#F4){ref-type="fig"}**). Finally, growth of the *bioA* transposon mutant was not restored by supernatants of *K. pneumoniae* and *E. coli*, suggesting that the presence of metabolically active cells of these organisms is required to complement the growth deficit (**Figure [4D](#F4){ref-type="fig"}**).

Discussion
==========

Our study identified metabolic pathways involved in either detrimental or beneficial interactions between *P. aeruginosa* and four bacterial respiratory pathogens. By screening a transposon library of 2,288 mutants in PA14, we identified mutants displaying altered growth inhibition, or growth phenotypes in the presence of co-colonizing bacterial species. We found that both *pqsC* and *carB*, responsible, respectively, for HAQ and uracil/pyrimidine synthesis, play an essential role in the direct competition of *P. aeruginosa* with *S. aureus*. Secondly, we identified *carB* and *purF*, the latter involved in purine synthesis, as essential for exploitative competition against *K. pneumoniae* and *B. cenocepacia* (**Figure [5](#F5){ref-type="fig"}**). Finally, we found that co-colonizing strains may also have beneficial effects, as illustrated by growth restoration of the *P. aeruginosa bioA* mutant by *K. pneumoniae* and *E. coli* (**Figure [5](#F5){ref-type="fig"}**).

Studies on microbial interactions have already revealed the role of the *Pseudomonas* quinolone signal (PQS) biosynthesis pathway in the inhibition of *S. aureus* growth. It has been demonstrated that 2-heptyl-4-quinolone *N*-oxide (HQNO), one of the final products of the *pqs* pathway, suppresses growth of Gram-positive bacteria, but not of Gram-negative bacteria ([@B27]). In aerobic conditions, HQNO binds to quinone-reacting cytochromes and inhibits respiratory electron transfer from quinone to cytochromes ([@B28]; [@B40]). The present study confirms the role of the PQS-biosynthesis pathway in the direct competition with *S. aureus*. Indeed, *pqsC* acts at the beginning of the metabolic PQS-pathway and its inactivation leads to the absence of all HAQs including PQS, 2-heptyl-4-quinolone (HHQ), as well as their N-oxide derivatives. The *pqsC* mutant identified in our screening was unable to inhibit growth of *S. aureus* in rich medium. The wild-type phenotype was partially restored in the *pqsC* mutant by complementation with plasmid-encoded copies of the *pqsCDE* genes. The partial complementation can be explained by a gene dosage effect due to overexpression from the constitutive promoter present on the vector plasmid pIApX2. In addition, we demonstrated that the PQS-pathway does not play a role under hypoxic conditions. This result was not unexpected since under hypoxic conditions, the aerobic respiratory chain is not functional and cannot be inhibited by HQNO ([@B27]). Furthermore, HQNO and PQS seem to be produced only under aerobic conditions due to the oxygen requirement of the PqsH mono-oxygenase to catalyze the final conversion of HHQ to PQS ([@B36]). This suggests that in the thickened mucous layers in the airways of CF patients, where low oxygen concentrations are prevailing ([@B46]), HQNO may play only a limited role in interference between *P. aeruginosa* and *S. aureus*. We can also hypothesize that the role of the PQS-system on *S. aureus* is limited in mixed biofilms, representing microaerophilic growth conditions. Nevertheless, HHQ and PQS were identified in sputum samples from CF patients ([@B6]; [@B31]) indicating that maybe, in the more oxygenated upper respiratory tract, HQNO might play a more prominent role in growth inhibition of Gram-positive bacteria.

Our results further suggest that the N-oxide derivatives of HAQs are responsible primarily for the *S. aureus* growth inhibition. As described above, the *pqsH* mutant was affected in the conversion of HHQ to PQS. PQS contributes to the positive feedback regulation of the pqsA-D genes via PqsR. Thus, a defect in PQS production should lead to the absence (or major decrease) of HHQ and HQNO in a *pqsH* mutant. In addition our results showed a small residual activity of the *pqsL* mutant, which displayed only a weak inhibition of *S. aureus* growth both on agar and in liquid. PqsL is a putative mono-oxygenase converting HHQ to HQNO, and PQS to its N-oxide derivative ([@B24]). A *pqsL* mutant was shown to produce increased amounts of PQS ([@B9]), and maybe also of other HAQs, suggesting that the non-*N*-oxide derivatives may also display a weak growth inhibitory effect on *S. aureus*.

In addition to the role of PQS, we demonstrated that the *P. aeruginosa carB* gene is required for direct competition with *S. aureus*. Without uracil, the *carB*-disrupted strain exhibited an alteration in its capacity to inhibit *S. aureus* growth. However, the growth of this mutant appeared to be slightly affected. Nevertheless, when we added uracil in the medium, the growth of the *carB*-disrupted strain was totally restored, but the inhibition of *S. aureus* growth was still diminished. Previous reports suggested that uracil influences all three QS*-*systems in *P. aeruginosa* (i.e., *las*, *rhl*, *pqs*; [@B41]). Since uracil is the final product of the biosynthesis pathway containing the *carB* gene, we tested if the phenotype exhibited by the *carB*-disrupted strain can be linked to QS. However, phenotypic analysis of QS-dependent traits showed that none of the three QS-systems was affected in the *carB*-disrupted strain. This indicates that a QS-unrelated mechanism was responsible for reduced inhibition of *S. aureus* growth in the *carB*-disrupted strain.

Interestingly, the *carB* gene also appeared essential for the exploitative competition between *P. aeruginosa* and *S. aureus*, as well as with *B. cepacia* and *K. pneumoniae*. These results suggest that *carB* is involved in the competition for resources between *P. aeruginosa* and these three competitors. CarB is an enzyme catalyzing the transformation of L-glutamine into carbamoyl-phosphate, an intermediate in the pyrimidine, arginine, and proline metabolisms (**Figure [5](#F5){ref-type="fig"}**). We show that the phenotype of the *carB*-disrupted strain can be restored by the addition of uracil, but not of arginine, demonstrating that the role of the *carB* gene in the exploitative competition can be associated to the pyrimidine biosynthesis pathway.

In addition to *carB*, the *purF* gene also appeared to be an essential gene for exploitative competition. Interestingly, growth of the *purF* mutant was not affected in the presence of Gram-positive bacteria (*S. aureus* and *S. epidermidis*) but was severely affected in grow in the presence of the Gram-negative strains tested (*B. cenocepacia, K. pneumoniae, E. coli*). The *purF* gene encodes an amidophosphoribosyltransferase involved in the conversion of L-Glutamine into 5-Phospho-ribosylamine, a primary product of the purine metabolism (**Figure [5](#F5){ref-type="fig"}**). Taken together, these results highlight the essential role of nucleic acid biosynthesis pathways for exploitative competition. Interestingly, the purine and pyrimidine synthesis pathways were also shown to be important for colonization of the mouse intestine by *E. coli* ([@B42]), an environment where invading organisms have to compete with resident microbial flora.

Finally, we identified beneficial interactions between *P. aeruginosa* and other lung co-colonizing species via the biotin synthesis pathway. Whereas a *P. aeruginosa bioA*-disrupted mutant was unable to grow on rich medium, the presence of *K. pneumoniae* and *E. coli* complemented the growth defect of this strain (**Figure [5](#F5){ref-type="fig"}**). In other words, the presence of *K. pneumoniae* and *E. coli* can be beneficial to *P. aeruginosa* when biotin supply is limited. However, the molecular basis of this beneficial interaction remains to be elucidated.

Conclusion
==========

Understanding the interactions between the various bacterial communities colonizing the CF-airways is of considerable importance as interactions can potentially affect the metabolism of pathogens, alter the population structure and eventually influence disease progression. It is clear from our experiments that complex interactions take place between CF-lung colonizing species which may lead to profound changes in bacterial community structures in CF-patients. Detrimental and beneficial interactions not only modulate the richness and the diversity of species but also create a complex environment in which bacterial species need to adapt to co-colonizing species aiming to increase their relative fitness. The metabolic pathways involved in these complex interactions could potentially be exploited to manipulate microbial population structure to improve the clinical outcome of chronic infectious.
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